Conclusions: Total ASG score consists of several subscores and attributes, not all of which predict outcomes. The aortic neck subscore was predictive of type IA endoleak and sac enlargement; AAA tortuosity and iliac calcification predicted 30-day reinterventions or 30-day implant complications. This study suggests that total ASG score can be simplified to reflect attributes most predictive of EVAR outcomes. Objective: Vascular grafts used for in situ tissue engineering processes may suffer not only from insufficient mechanical properties but also from vulnerabilities related to their biocompatibility. Bicomponent composite degradable vascular grafts were developed with superior mechanical properties and long-term anticoagulant activity to meet the requirement of small-diameter vascular prostheses with high performance.
Objective: Vascular grafts used for in situ tissue engineering processes may suffer not only from insufficient mechanical properties but also from vulnerabilities related to their biocompatibility. Bicomponent composite degradable vascular grafts were developed with superior mechanical properties and long-term anticoagulant activity to meet the requirement of small-diameter vascular prostheses with high performance.
Methods: Composite vascular graft (cVG) prototypes were created by combining a flexible polylactic acid (PLA) knitted fabric with a soft polycaprolactone (PCL) matrix. Two types of cVG (cVG-H and cVG-L) with different density of PLA fabric were developed using a PCL coating and a freeze-drying fabrication method. The inner surface of a cVG was subjected to a covalent and electrostatic adsorption through a "two-step" heparinization process (Fig) . The mechanical properties and anticoagulation features were carried out in vitro to evaluate the characteristics of the cVG.
Results: As shown in the Fig, the cVG exhibited a uniformly normal structure with a compact interface combination of the PLA multifilament and the PCL matrix as well as a good deformability of the vascular membrane. The cVG had higher strength than commercial expanded polytetrafluoroethylene samples. The radial strength of cVG-H was twice as high as that of cVG-L, and cVG-H also featured a better compliance. The excellent compression recovery of the cVG also demonstrated the advantage of the composite structure. In addition, the two-step modification of the cVG (PCL-LBL) showed a better anticoagulation behavior compared with the covalent grafting heparin cVG (PCL-HEP), even in the context of this mucopolysaccharide released for a month.
Conclusions: An in situ tissue engineering-oriented vascular graft was designed, developed, and characterized. These vascular graft prostheses have good mechanical and long-term anticoagulant properties. This work provides data support to the development of in situ tissue engineering vascular grafts and guides breeding research in the development of small-diameter blood conduits. Objective: The risk of 30-day unplanned readmission in diabetic foot ulcer (DFU) patients is nearly 20%. Our aim was to quantify the cost of readmissions in patients admitted with DFU.
Methods: All patients presenting to our multidisciplinary diabetic limb preservation service (June 2012-June 2016) were enrolled in a prospective database. Inpatient costs and net margins (U.S. dollars) were calculated overall and for index admissions vs 30-day unplanned readmissions.
Results: A total of 249 admissions in 150 patients were included. Of these, 206 admissions were index admissions and 43 were 30-day readmissions. The most common reason for readmission was the foot wound (49%), followed by bypass wound (14%), renal (9%), and other systemic complications. Surgical interventions during readmission were common (47%) and included both podiatric (37%) and vascular (23%) interventions. The mean hospital cost per admission was $25,915 6 $1309 and did not differ between index admissions and readmissions ($25,649 6 $2384 vs $28,792 6 $4902; P ¼ .59). However, there was a trend toward lower hospital net margins after readmissions ($4978 6 $1010 vs $2700 6 $1289; P ¼ .07). The overall cost of care for patients requiring readmission was significantly higher than for patients who were not readmitted ($115,288 6 $19,325 vs $42,525 6 $3664; P < .001). During the course of the study period, DFU care at our institution cost $7.9 million, of which $1.2 million (15%) was attributable to readmission costs. Wound healing outcomes were favorable, with 78% of all wounds achieving healing by 1 year.
Conclusions: The cost of readmissions for DFU patients is just as high as the cost of the index admissions, but with lower hospital net margins. When it is extrapolated to national data, the 15% readmission cost burden that we report is equivalent to $210 million in hospital costs annually. Focused efforts at preventing readmissions in this population of high-risk patients are essential to reducing the overall costs of care associated with DFU.
Author Disclosures: C. Hicks: Nothing to disclose; J. Canner: Nothing to disclose; H. Karagozlu: Nothing to disclose; N. Mathioudakis: Nothing to disclose; R. Sherman: Nothing to disclose; J. Black: Nothing to disclose; C. Abularrage: Consultant-Medtronic. Methods: Using hashtags, our local VQI registry collected these unique variables starting in July 2017: intraoperative Foley use and removal; alpha blocker or 5a-reductase inhibitor use; prior benign prostatic hyperplasia surgery; and POUR, defined as reinsertion of a urethral catheter. Inclusion criteria were male patients older than 18 years presenting for EVAR. Use and management of Foley catheters were at the surgical teams' discretion. We present our interim analysis results up to December 31, 2017, inclusive. Fisher exact test and Student t-test were used to compare differences between categorical and continuous variables, respectively.
Results: There were 46 patients included, with a mean age of 73.1 years. Two patients (4.3%) developed POUR. Comparing patients with and without POUR, length of stay was significantly different (9 vs 2.1 days; P ¼ .01) but not intraoperative Foley use (2 vs 25; P ¼ .62), Foley removal on postoperative day 0 (0 vs 9; P ¼ .32) or day 1 (2 vs 14; P ¼ .27), operative time (142 vs 146 minutes; P ¼ .7), benign prostatic hyperplasia medication use (0 vs 11; P ¼ .62), or surgery (0 vs 1; P ¼ .88).
Conclusions: We implemented a novel VQI hashtag method to prospectively collect Foley and POUR outcomes in EVAR patients. Rates of POUR were low, and variability in Foley catheter use and management was observed. Ongoing data collection is required to make formal recommendations about Foley catheter use in this population.
Author Disclosures: R. McClarty: Nothing to disclose; M. Assmus: Nothing to disclose; P. Dawe: Nothing to disclose; Y. Abdulrehman: Nothing to disclose. Objective: The objective of this study was to evaluate the impact of growth factors or treatments high in growth factors on patients with lower limb chronic venous leg ulcers (VLUs).
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE and Embase up to February 2018 were searched. Studies were eligible for inclusion if they compared a growth factor vs placebo or standard care in patients with VLUs. Two reviewers independently selected RCTs and assessed risk of bias. The primary outcome measure was complete wound healing, and secondary outcomes were percentage reduction in wound area and adverse events. Pooled proportions of patients were calculated using a random-effects model, and heterogeneity among studies was assessed using inconsistency statistic and subgroup analyses.
Results: From 1460 studies, we included 12 RCTs (n ¼ 722). RCTs assessed platelets (platelet lysate, platelet gel, platelet-rich growth factor, platelet-rich plasma, platelet-rich fibrin), keratinocyte growth factor 2, endothelial growth factor, transforming growth factor b2, and granulocyte-macrophage colony-stimulating growth factor. There was no significant difference between any growth factor and placebo in complete wound healing (437/722 [59.97%] vs 285/722 [39.47%]; relative risk, 1.34, 95% confidence interval, 0.94-1.90, P ¼ .10; I 2 ¼ 71%, 11 trials; low-quality evidence). Subgroup analysis indicated that granulocyte-macrophage colony-stimulating growth factor held a significant increase in the number of wounds completely healed, whereas placebo demonstrated significantly more wounds completely healed compared with keratinocyte growth factor 2. When any growth factor was compared with placebo, there was a significant increase in percentage wound reduction by 48.72% (95% confidence interval, 39.14-58.30; P < .00001; I 2 ¼ 0%, four trials; low-quality evidence). There was no significant difference in overall adverse event rate.
Conclusions: In patients with chronic VLUs, growth factors have nonsignificant effect in complete wound healing. However, growth factors may increase percentage reduction in wound area. This suggests
